Aldosterone synthase inhibitors
US-9073929-B2 · Jul 7, 2015 · US
Aldosterone synthase inhibitors
US9278093B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9278093-B2 |
| Application number | US-201314389172-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 29, 2013 |
| Priority date | Apr 4, 2012 |
| Publication date | Mar 8, 2016 |
| Grant date | Mar 8, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
First claim
Opening claim text (preview).
We claim: 1. A compound of the formula: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 which is or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 which is or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 which is or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 which is or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 7. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of at least one additional therapuetic agent and a pharmaceutically acceptable carrier. 8. A method for the treatment or amelioration of one or more of the conditions associated with inhibiting CYP11B2, which comprises administering therapeutically effective amount of at least one compound as defined in claim 1 or a pharmaceutically acceptable salt thereof to mammal in need of such treatment, wherein the conditions that could be treated or ameliorated by inhibiting CYP11B2 are hypertension, left ventricular diastolic dysfunction, renal failure, retinopathy. 9. A method for inhibiting CYP11B2 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A61K31/4745Primary
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9278093B2 cover?
- This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated b…
- Who is the assignee on this patent?
- Merck Sharp & Dohme, Elexopharm Gmbh
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4745. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).